News | Radiation Dose Management | April 25, 2017

Corindus Announces Strategic Partnership with BLOXR Solutions to Distribute Radiation Protection Products

Addition of lightweight radiation protection apparel provides extra safety for entire cath lab team

Corindus Announces Strategic Partnership with BLOXR Solutions to Distribute Radiation Protection Products

April 25, 2017 — Corindus Vascular Robotics Inc. announced a strategic partnership with BLOXR Solutions, provider of radiation protection products designed to reduce exposure for clinicians and patients. The three-year distribution agreement grants Corindus the non-exclusive rights to distribute BLOXR's radiation protection products globally and provides BLOXR with additional reach into the interventional cardiology space. Under the agreement, Corindus may sell the entire BLOXR line, which offers multiple types of protective equipment including aprons, thyroid collars and caps.

Corindus' CorPath System, the first robotic-assisted percutaneous coronary intervention (PCI) platform cleared by the U.S. Food and Drug Administration (FDA), has been shown* to reduce radiation exposure to the primary operator by 95 percent1 by positioning them behind a radiation-shielded interventional workstation. Clinical trials with the CorPath System* have also shown a 15 percent2 reduction in radiation exposure for cath lab staff, which can potentially be further enhanced by the addition of the BLOXR line of lightweight protective apparel. BLOXR XPF apparel, which has the potential to further reduce the orthopedic burden for these critical team members, is a patented, comfortable, lightweight material that can be bent and folded without cracking, provides 0.5mm lead equivalent protection and is guaranteed for three years.

For more information: www.corindus.com

References

1. Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J Am Coll Cardiol. 2013; 61(15):1596-1600.
2. Campbell et al. Staff Exposure to X-ray during PCI: Randomized Comparison of Robotic vs Manual Procedures. Presented at SCAI 2016.
* Studies conducted using CorPath 200 System.

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init